Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07145489 · ClinicalTrials.gov registry record · NA
Infrared Photobiomodulation in Humans With Epilepsy
A NA study of Drug Resistant Epilepsy, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT07145489: Recruiting NA study of Drug Resistant Epilepsy, sponsored by Beth Israel Deaconess Medical Center.
NCT07145489 is a NA study of Drug Resistant Epilepsy that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 13 participants, below the 35-participant average among 6 other Drug Resistant Epilepsy trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07145489, a NA study of Drug Resistant Epilepsy, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.
Primary Outcome
fraction of seizures reduced by therapy assessed by individual baseline rate
Conditions Studied
Interventions
- DEVICE photobiomodulation
Study Locations (1)
Massachusetts
- BIDMC - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2025-11-25 |
| Est. Completion | 2027-09-25 |
| Phase | NA |
What NCT07145489 shows while recruiting
NCT07145489 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 35-participant average among 6 other Drug Resistant Epilepsy trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Drug Resistant Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which photobiomodulation is the first listed.
NCT07145489 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07145489 about?
NCT07145489 is a clinical study titled "Infrared Photobiomodulation in Humans With Epilepsy". Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise a...
What is the current status of trial NCT07145489?
This trial is currently recruiting. It is a NA study. The enrollment target is 13 participants. The study started on 2025-11-25. Estimated completion is 2027-09-25.
What conditions does trial NCT07145489 study?
This clinical trial studies the following conditions: Drug Resistant Epilepsy.
What interventions are being tested in trial NCT07145489?
The interventions under investigation include: photobiomodulation (DEVICE).
Who is sponsoring clinical trial NCT07145489?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07145489 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Drug Resistant Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial
RECRUITING · NA
-
Goals for Epilepsy Clinic Visits Trial
RECRUITING · NA
-
Novel Helmet Design in Patients With Seizures
COMPLETED · NA
-
Electrophysiologic Studies of Cognition in Epilepsy Patients
COMPLETED · NA
-
The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy
RECRUITING · Phase 2
-
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI